Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
14 hedge funds and large institutions have $70.6M invested in Ambrx Biopharma Inc in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.88% more ownership
Funds ownership: 48.15% → 49.03% (+0.88%)
13% less funds holding
Funds holding: 16 → 14 (-2)
54% less capital invested
Capital invested by funds: $152M → $70.6M (-$81.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$2.22M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$530K |
| 3 |
Renaissance Technologies
New York
|
+$55.2K |
| 4 |
Millennium Management
New York
|
+$30.7K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$563 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$959K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$152K |
| 3 |
CCM
CAAS Capital Management
New York
|
-$118K |
| 4 |
BlackRock
New York
|
-$92.1K |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$1K |
AMAM Hedge Fund Activity: Q1 2022 in Review
14 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2022, worth a combined $70.6M — down 54% from $152M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AMAM and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Suvretta Capital Management, adding an estimated $2.22M. The largest seller was Octagon Capital Advisors, cutting an estimated $959K.
- 14 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2022, down from 16 in Q4 2021.
- Funds reported $70.6M of Ambrx Biopharma Inc stock for Q1 2022, down 54% quarter-over-quarter.
- 0 funds opened new Ambrx Biopharma Inc positions in Q1 2022 and 2 closed out, a net change of -2 holders.
- The largest Ambrx Biopharma Inc buyer in Q1 2022 was Suvretta Capital Management, an estimated $2.22M added.
- The largest Ambrx Biopharma Inc seller in Q1 2022 was Octagon Capital Advisors, an estimated $959K sold.
Based on aggregated 13F filings for Q1 2022.